The need for more precise and personalized risk prediction in patients with atrial fibrillation (AF) is undeniable. Biomarkers offer this possibility. Below, we summarize the Oyama et al. 2021 paper which reports that reassessment of the ABC risk scores at 12 months accurately reclassified a significant proportion of patients compared with their baseline risk. This could allow for an exciting possibility of a new direction for monitoring patients with AF and a dynamic risk of future events.
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.
Oyama K, Giugliano RP, Berg DD, Ruff CT, Jarolim P, Tang M, Murphy SA, Lanz HJ, Grosso MA, Antman EM, Braunwald E, Morrow DA.